An interventional study of DE-iPTV in Brain Metastases, Adult and Breast Cancer, sponsored by Imperial College London. Recruiting at 2 sites in United Kingdom. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Brain Neoplasms with a site in United Kingdom — 18 open to participants now, 29 under way, 5 of them phase 3. Brain Neoplasms · United Kingdom.
Among the 88 studies in Brain Neoplasms with a site in United Kingdom, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 15 with no phase, reaches primary completion later than 18 of the 28 other live ones, and was the 83rd registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →18 of the 88 studies in Brain Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
The Leeds Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 18–80
Cancer Research UK · Sites in United Kingdom
University College, London · Sites in United Kingdom
Ages 18+
Rigel Pharmaceuticals · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 12–39
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 16 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 32 · Phase 3 23
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 120 across the 72 interventional studies, 87 across the 14 observational. Of the 49 that completed or were terminated, 14 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 88 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Brain Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT04478279Sapience TherapeuticsA Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | 2026-12 |
| NCT07558395Institut National de la Santé Et de la Recherche Médicale, FranceEffectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour | 2026-12 |
| NCT07384884King's College Hospital NHS TrustSurgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas | 2026-12-31 |
| NCT07134842University College, LondonA Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 88 studies in Brain Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.
The main questions that have been set out to to answer are:
Participants will:
Brain metastases from breast cancer are a common, and devastating, complication with survival times of 3 - 5 months from diagnosis.
The main treatment approaches to brain metastases are surgery, stereotactic radiosurgery (SRS), and whole brain radiotherapy. However, it is known that most patients with brain metastases receive either whole-brain radiotherapy (WBRT) or no treatment, with relatively low rates of surgery and SRS. Since the commonest treatment in those who do have treatment is WBRT, the local team have developed an approach that is believed to be (possibly) more effective than WBRT. The objective is to evaluate this approach in patients who are not suitable to receive more aggressive treatment and who would otherwise receive WBRT. The local approach involves using a modern radiotherapy planning approach, combined with careful, intra-metastasis dose escalation (Dose Escalated internal PTV (DE-iPTV)) to deliver a higher dose to tumour, while delivering less dose to the brain. The combination of less dose to normal structures and more dose to the lesion will hopefully improve Health-related Quality of Life (HRQoL).
The aim of this study is to demonstrate the feasibility of delivering complex radiotherapy, dose escalated internal PTV (DE-iPTV), and measuring quality of life at 8 weeks post-enrolment for patients with brain metastases from breast cancer who would otherwise receive WBRT. An exploratory blood-based biomarker sample collection and analysis will be completed. Furthermore, linked national cancer data will be used to measure the number of patients currently offered WBRT, including survival costs and hospital admissions, and thus provide a baseline to estimate the impact of this novel approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo a radiotherapy planning scan, and an upto date MRI brain with contrast. Patients will receive 5 fractions of DE-iPTV radiotherapy over 1 week.
Radiation: DE-iPTV
Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
Feasibility of delivering DE-iPTV and measuring health related quality of life questionnaire in patients with brain metastases from breast cancer to whom their treating clinician would normally offer whole brain radiotherapy
Completion of radiotherapy and completion of EuroQol- 5 Dimension (EQ-5D-5L) questionnaire
Time frame: 8 weeks post-enrolment
Lesional Response
Lesional response and intracranial progression measured using RANO-BM criteria
Time frame: 8 weeks
Intracranial progression
Intracranial progression based on RANO-BM
Time frame: 3 months
Intracranial progression
Intracranial progression based on RANO-BM
Time frame: 6 months
Treatments
Use of further brain-directed therapies (reported by clinician)
Time frame: Within 6 months of enrolment
Central Nervous System (CNS) Failures
Time to CNS failure (either lesional progression or developing a new lesion as per RANO-BM)
Time frame: Within 6 months of enrolment
Neurological toxicities
Acute and late neurological/ CNS toxicity as assessed using CTCAE v5
Time frame: Within 6 months of enrolment
Health Related Quality of Life
HRQoL over time (participants reported outcomes for descriptive analysis)
Time frame: Within 6 months of enrolment
Time to deterioration in quality of life
Time to deterioration in Health Related Quality of Life - measured as time to first time there is a minimum clinically significant change in EuroQol- 5 Dimension (EQ-5D-5L)
Time frame: Within 6 months of enrolment
Symptom Burden
Symptom burden assessed by collection of clinician-recorded toxicities
Time frame: Within 6 months of enrolment
Steroid usage
Use of corticosteroids over time, assessed through clinician reports and patient diaries
Time frame: Within 6 months of enrolment
Quality-Adjusted Life Year
Quality-Adjusted Life Year
Time frame: Within 6 months of enrolment
Overall survival
Overall survival
Time frame: End of study
Changes in blood-based biomarkers
Change between baseline and week 8 levels of Circulating Tumour DNA (ctDNA) and S100
Time frame: 8 weeks
Imaging Changes
MRI-based response (as per RANO-BM and serial volumetric measurements)
Time frame: Up to 6 months post enrolment
Radiation Necrosis
Radiation necrosis based on radiologist report
Time frame: Up to 6 months post enrolment
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 18 months is below that.
Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Jan 2025 → Jun 2026, primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.